Edition:
United Kingdom

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

411.30DKK
2:59pm BST
Change (% chg)

kr.-4.00 (-0.96%)
Prev Close
kr.415.30
Open
kr.413.80
Day's High
kr.414.20
Day's Low
kr.408.60
Volume
98,323
Avg. Vol
321,804
52-wk High
kr.477.70
52-wk Low
kr.280.80

Summary

Name Age Since Current Position

Lars Rasmussen

58 2016 Independent Chairman of the Board

Deborah Dunsire

55 2018 President, Chief Executive Officer

Lene Skole-Soerensen

59 2015 Deputy Chairman of the Board

Anders Goetzsche

50 2018 Chief Financial Officer, Executive Vice President

Peter Anastasiou

48 2017 Executive Vice President, North America

Lars Bang

55 Executive Vice President, Supply Operations & Engineering

Anders Gersel Pedersen

66 2011 Executive Vice President, Research and Development

Jacob Tolstrup

45 2017 Executive Vice President, Commercial Operations

Henrik Andersen

50 2018 Director

Jeffrey Berkowitz

2018 Director

Lars Holmqvist

58 2015 Director

Rikke Kruse Andreasen

2018 Director, Employee Representative

Joern Moeller Mayntzhusen

51 2008 Directors, Employee Representative

Ludovic Tranholm Otterbein

2018 Director, Employee Representative

Jeremy Levin

65 2017 Independent Director

Palle Holm Olesen

Vice President Investor Relations

Biographies

Name Description

Lars Rasmussen

Mr. Lars Soeren Rasmussen has served as Independent Chairman of the Board of Directors at H. Lundbeck A/S since March 31, 2016. Before that, he has been Independent Director of the Company since March 21, 2013. He is Member of the Company’s Audit Committee and Chairman of the Remuneration Committee. He has been Chief Executive Officer of Coloplast A/S since 2008 and Member of the company's Executive Management since 2001. He has management experience in global med-tech. He was responsible for various functions in the group, including global sales, innovation and production, both in Denmark and the United States. He is Member of the Board of Directors of William Demant Holding A/S.

Deborah Dunsire

Dr. Deborah L. Dunsire has been appointed President and Chief Executive Officer of H. Lundbeck A/S, effective as of September 1, 2018. She brings more than 30 years of clinical, commercial, and international management experience from the biotech and pharmaceutical industry, primarily in the fields of oncology and CNS, thus bridging a breadth of scientific and business experience. Her wealth of professional and executive experience includes positions as President and CEO of XTuit Pharmaceuticals, Inc., FORUM Pharmaceuticals Inc. and Millennium Pharmaceuticals, Inc.

Lene Skole-Soerensen

Ms. Lene Skole-Soerensen has been Deputy Chairman of the Board at H. Lundbeck A/S since March 25, 2015. She is CEO of Lundbeck Foundation and holds directorships in two subsidiaries. She is Member of the Remuneration and Scientific Committees of the Company. She also serves as Deputy Chairman of the Boards of Oersted A/S, Falck A/S, TDC A/S and ALK-Abello A/S and is Board Member of Tryg A/S and Tryg Forsikring A/S.

Anders Goetzsche

Mr. Anders Goetzsche is Executive Vice President and Chief Financial Officer of H. Lundbeck A/S. He no longer serves as Interim Chief Executive Officer of the Company, effective as of September 1, 2018. He has held that position from November 1, 2017. He joined the Company in 2007. Prior to that, he was Chief Financial Officer for the Berlingske Officin, Director of Group Accounting and Reporting at Group 4 Falck and Sales Manager with the SAS Institute. He started his career in 1991 at PriceWaterhouseCoopers. Mr. Goetzsche is Member of the Board of Veloxis Pharmaceuticals A/S and Chairman of the Board of Rosborg Moebler A/S. He received a Master of Science degree in Accounting from Syddansk Universitet (University of Southern Denmark) in 1991, and became State Authorized Public Accountant in 1997.

Peter Anastasiou

Mr. Peter E. Anastasiou has been appointed Executive Vice President, North America at H. LUNDBECK A/S, effective as of November 1, 2017. Peter Anastasiou serves as President of Lundbeck North America, overseeing the operations of both the U.S. and Canadian businesses. Peter Anastasiou has been with Lundbeck since 2009 and has since early 2016 served as President of Lundbeck U.S. where he oversees all aspects of the U.S. value chain, directing all Commercial, Drug Development and Corporate activities. Prior to that he served as U.S. Chief Commercial Officer, during which time he directed the Commercial operations of the company’s Psychiatry and Neurology franchises. Since mid-2016, Peter Anastasiou has had the responsibility for North America including Canada. Before joining Lundbeck, Peter Anastasiou held a series of leadership roles within neuroscience-focused pharmaceutical organizations. He served as Vice President of Marketing and Reimbursement at Neuronetics, Inc., and as Director of Abilify U.S. Marketing at Bristol-Meyers Squibb Company. He began his career at Eli Lilly and Company, where he held a variety of Marketing and Sales positions over the course of 11 years, including participation in the global launch of Cymbalta. He is Member of the Board of The Bear Necessities Pediatric Cancer Foundation and PhRMA (Pharmaceutical Research and Manufacturers of America).

Lars Bang

Mr. Lars Bang serves as Executive Vice President, Supply Operations & Engineering at H. Lundbeck A/S. He began his career at the Company in 1988 as Trainee in Research & Development (R&D). Over the years, he held such positions as Lunbeck's Divisional Director for Corporate Planning and Strategy; Group Senior Vice President Supply Operations and Engineering since 2003, and Senior Vice President, Sales & Marketing, among others. He joined the Executive Management in February 2016. Mr. Bang is Member of the Board of Directors of Fertin Pharma A/S, Claudio Bidco A/s, Claudio Hodco A/S and OB Holding. He obtained a Master of Science degree in Engineering from Danmarks Tekniske Universitet in 1987 and a Bachelor of Commerce degree in Marketing from the Copenhagen Business School in 1989.

Anders Gersel Pedersen

Dr. Anders Gersel Pedersen M.D., Ph.D. has served as Executive Vice President, Research and Development of H. Lundbeck A/S since September 7, 2011. He joined the Company in 2000 as Vice President of International Clinical Research and was later appointed Executive Vice President of Drug Development. Prior to Lundbeck, he worked for Eli Lilly for 11 years, including ten years as a director overseeing worldwide clinical research in oncology. He started his carrier as researcher at Copenhagen hospitals. Dr. Gersel Pedersen has experience as Member of the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, the American Society of Clinical Oncology, the Danish Society of Medical Oncology and the Danish Society of Internal Medicine. He serves as Member of the Board of Directors of ALK-Abello A/S and Deputy Chairman of the Boards of Bavarian Nordic A/S and Genmab A/S. He holds a degree in Medicine.

Jacob Tolstrup

Mr. Jacob Tolstrup has been appointed Executive Vice President, Commercial Operations at H. Lundbeck A/S, effective as of November 1, 2017. He has previously been Executive Vice President, Corporate Functions at the Company since February 2016. Jacob Tolstrup began his career with Abbott Laboratories in 1997. In 1999, he joined Lundbeck and has since been working in a number of positions including Finance, Investor Relations and Communication and has worked in Lundbeck affiliates in the US for approximately four years. He is head of Corporate Functions which comprises Corporate Business Development, Corporate Human Resources, Investor Relations and Corporate Communication & Public Affairs. Jacob Tolstrup holds a Master of Science in Business Administration & Commercial Law from Aalborg University, Denmark and an MBA from European Business College, Munich, Germany.

Henrik Andersen

Jeffrey Berkowitz

Mr. Jeffrey (Jeff) Berkowitz, J.D. has been Director of H. LUNDBECK A/S since March 20, 2018. He is Member of the Scientific Committee of the Company.

Lars Holmqvist

Mr. Lars Erik Holmqvist has been Director of H. Lundbeck A/S since March 25, 2015. He is Member of the Audit Committee. He holds Master of Science in business administration. Lars Holmqvist is Senior Advisor within healthcare at Bain Capital. He previously served as Vice President responsible for sales and marketing at Pharmacia. In addition, he has held management positions in several pharma and med-tech companies including Boston Scientific Corporation, Medtronic, Applied Biosystems Group, DAKO and Agilent Technologies. Lars Holmqvist’s special qualifications for serving on Lundbeck’s Board of Directors include his international management experience, his expertise in finance and his sales and marketing experience from the global pharmaceutical, med-tech and life-science industry. Lars Holmqvist is Board Member at Lundbeck Foundation, ALK-Abello A/S, Tecan AG Naka UK topco Ltd.

Rikke Kruse Andreasen

Joern Moeller Mayntzhusen

Mr. Joern Moeller Mayntzhusen has been Employee Representative on the Board of Directors of H. Lundbeck A/S since 2008. He is Project Director at the Company. He joined Lundbeck in 2002 and has since been responsible for Production Planning and Costing and served as Head of Customer Supply. Mr. Mayntzhusen started his carrier at Handelsbanken (1986-1990). Later on, he spent two years at Thule Air Base with Greenland Contractors (1990-1992). In 1992 he started studying for his Bachelor of Science degree and was employed as Logistic Assistant with Braun Nordic (1993-1997). For the next two years Mr. Mayntzhusen worked as Business Management Advisor with Mellemfolkeligt Samvirke in Zimbabwe. Prior to joining Lundbeck, he was Nordic Logistic Manager with Moulinex Krups (1999-2002). Mr. Mayntzhusen obtained a Bachelor of Science degree in Logistics (HD(L)) from Copenhagen Business School in 1995, and a Master of Business Administration degree from Edinburgh Business School in 2002.

Ludovic Tranholm Otterbein

Jeremy Levin

Dr. Jeremy Max Levin has served as Independent Member of the Board of H. Lundbeck A/S since March 30, 2017. He is Member of the Company’s Scientific Committee. He serves as CEO and Chairman of Ovid Therapeutics. He is also Board Member of BioCon, ZappRx and BIO (Biotechnology Innovation Organization in the US).

Palle Holm Olesen